Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30117145 | 0.82 | CYP11B1 (0.41) | ACACBMGLLHCRTR2HCRTR1GRM5 | |
| SCHEMBL25417413 | 0.82 | CYP11B1 (0.41) | ACACBMGLLHCRTR2HCRTR1GRM5 | |
| SCHEMBL10164882 | 0.82 | HCRTR2 (0.43) | ACACBMGLLHCRTR2HCRTR1GRM5 | |
| SCHEMBL5262266 | 0.81 | MAP3K12 (0.48) | MGLLHCRTR2HCRTR1MAP3K12HRH3 | |
| SCHEMBL447719 | 0.79 | LOX (0.47) | ACACBHCRTR2HCRTR1GRM5CLK4 | |
| SCHEMBL29867993 | 0.79 | LOX (0.47) | ACACBHCRTR2HCRTR1GRM5CLK4 | |
| SCHEMBL6247699 | 0.79 | ACACB (0.37) | ACACBMGLLHCRTR2HCRTR1GRM5 | |
| SCHEMBL446431 | 0.79 | MGLL (0.42) | ACACBMGLLHCRTR2HCRTR1MAP3K12 | |
| SCHEMBL447841 | 0.79 | MGLL (0.50) | MGLLHCRTR2HCRTR1MAP3K12HRH3 | |
| SCHEMBL4930416 | 0.76 | GABRG2 (0.49) | ACACBMGLLHCRTR2HCRTR1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583849-B2 | KCNT1 inhibitors and methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4692069-A2 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4110317-B1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| EP-4110317-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-7541466-B2 | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases | GENZYME CORPORATION (US) | 2009-06-02 | — | — | US | disclosed |
| US-20050176761-A1 | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases | GENZYME CORPORATION (US) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583849-B2 | KCNT1 inhibitors and methods of use | KCNT1, SCN1A, KCNT2 | ACACB 2088/4885MGLL 2724/4885HCRTR2 517/4885 |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | ACACB 3348/4885MGLL 4133/4885HCRTR2 751/4885 |
| US-20050176761-A1 | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases | CFTR, NPC1L1, GOLT1B | ACACB 1811/4885MGLL 1778/4885HCRTR2 1766/4885 |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | ACACB 3348/4885MGLL 4133/4885HCRTR2 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.